Myocardial fibrosis as the first sign of cardiac involvement in a male patient with Fabry disease: Report of a clinical case and discussion on the utility of the magnetic resonance in Fabry pathology

BMC Cardiovascular Disorders

Volumn 14, Issue , 2014, Pages

  Sechi, Annalisa ^a   Nucifora, Gaetano ^a   Piccoli, Gianluca ^a   Dardis, Andrea ^a   Bembi, Bruno ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Cardiovascular magnetic resonance; Fabry disease; Late gadolinium enhancement; Myocardial fibrosis

Indexed keywords

AGALSIDASE ALFA; GADOLINIUM; ALPHA GALACTOSIDASE; ALPHA-GALACTOSIDASE A, HUMAN; CONTRAST MEDIUM;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CASE REPORT; CAUCASIAN; CLINICAL FEATURE; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; FABRY DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE WALL; HEART MUSCLE FIBROSIS; HUMAN; MALE; PATIENT MONITORING; PRIORITY JOURNAL; STAGING; YOUNG ADULT; DIAGNOSTIC USE; ENZYMOLOGY; FIBROSIS; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HEART MUSCLE; MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; SEX DIFFERENCE;

ALPHA-GALACTOSIDASE; CONTRAST MEDIA; DNA MUTATIONAL ANALYSIS; FABRY DISEASE; FIBROSIS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; MALE; MUTATION; MYOCARDIUM; PHENOTYPE; PREDICTIVE VALUE OF TESTS; SEX FACTORS; YOUNG ADULT;

EID: 84904272943     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-14-86     Document Type: Article

References (17)

1. Desnick R, Ioannou Y, Eng C. Alpha-Galactosidase A deficiency: Fabry disease. The Metabolic and Molecular Bases of Inherited Disease 2001, 3733-3774. New York: McGraw-Hill, Scriver CR BA, Sly WS, Valle D, 8.
2. Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M, . European FOS Investigators Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 2006, 43:347-352. 2563231, 16227523, European FOS Investigators.
3. Martins AM, D'Almeida V, Kyosen SO, Takata ET, Delgado AG, Gonçalves AM, Benetti Filho CC, Martini Filho D, Biagini G, Pimentel H, Abensur H, Guimarães HC, Gomes JG, Sobral Neto J, D'Almeida LO, Carvalho LR, Harouche MB, Maldonado MC, Nascimento OJ, Montoril PS, Bastos RV. Guidelines to diagnosis and monitoring of Fabry disease and review of treatment experiences. J Pediatr 2009, 155(4 Suppl):S19-S31.
4. Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 2006, 69:1216-1221. 10.1038/sj.ki.5000208, 16609685.
5. Engelen MA, Brand E, Baumeister TB, Marquardt T, Duning T, Osada N, Schaefer RM, Stypmann J. Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster Study (FaMuS) data. BMJ Open 2012, 21:2(6).
6. Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M, Sunder-Plassmann G, . FOS Investigators Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet 2009, 46:548-552. 10.1136/jmg.2008.065904, 19473999, FOS Investigators.
7. Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, Leed PJ, Elliott PM. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003, 24:2151-2155. 10.1016/j.ehj.2003.09.017, 14643276.
8. Weidemann F, Breunig F, Beer M, Sandstede J, Störk S, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 2005, 26:1221-1227. 10.1093/eurheartj/ehi143, 15728649.
9. Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M, Machann W, Voelker W, Ertl G, Wanner C, Weidemann F. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging 2011, 4:592-601. 10.1016/j.jcmg.2011.01.020, 21679893.
10. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WR. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003, 138:338-346. 10.7326/0003-4819-138-4-200302180-00014, 12585833.
11. Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006, 8:539-548. 10.1097/01.gim.0000237866.70357.c6, 16980809.
12. Gange CA, Link MS, Maron MS. Utility of cardiovascular magnetic resonance in the diagnosis of Anderson-Fabry disease. Circulation 2009, 120:e96-e97. 10.1161/CIRCULATIONAHA.109.849828, 19786638.
13. Nucifora G, Miani D, Di Chiara A, Piccoli G, Artico J, Puppato M, Slavich G, De Biasio M, Gasparini D, Proclemer A. Infarct-like acute myocarditis: relation between electrocardiographic findings and myocardial damage as assessed by cardiac magnetic resonance imaging. Clin Cardiol 2013, 36:146-152. 10.1002/clc.22088, 23280562.
14. Thompson RB, Chow K, Khan A, Chan A, Shanks M, Paterson I, Oudit GY. T1 mapping with cardiovascular MRI is highly sensitive for fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging 2013, 6:637-645. 10.1161/CIRCIMAGING.113.000482, 23922004.
15. Sengupta PP, Korinek J, Belohlavek M, Narula J, Vannan MA, Jahangir A, Khandheria BK. Left ventricular structure and function: basic science for cardiac imaging. J Am Coll Cardiol 2006, 48:1988-2001. 10.1016/j.jacc.2006.08.030, 17112989.
16. Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Störk S, Voelker W, Ertl G, Wanner C, Strotmann J. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 2009, 119:524-529. 10.1161/CIRCULATIONAHA.108.794529, 19153271.
17. Beer M, Weidemann F, Breunig F, Knoll A, Koeppe S, Machann W, Hahn D, Wanner C, Strotmann J, Sandstede J. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol 2006, 97:1515-1518. 10.1016/j.amjcard.2005.11.087, 16679096.